Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT07265570

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

Led by InSilico Medicine Hong Kong Limited · Updated on 2026-03-31

80

Participants Needed

28

Research Sites

89 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients with active ulcerative colitis.

CONDITIONS

Official Title

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand the study and provide written informed consent.
  • Female participants must not be pregnant or breastfeeding.
  • Willing to use effective contraception from screening until 3 months after last dose and no plans for sperm or egg donation during this period.
  • Age between 18 and 75 years at the time of consent.
  • Diagnosed with ulcerative colitis for at least 3 months before screening colonoscopy and meet protocol criteria.
  • Meet relevant criteria if using or discontinuing concomitant medications defined in the protocol.
Not Eligible

You will not qualify if you...

  • Suspected or diagnosed Crohn's disease, undefined colitis, ischemic colitis, fulminant colitis, toxic megacolon, radiation colitis, gastrointestinal perforation (other than appendicitis or penetrating injury), diverticular disease with colitis, enterophthisis, abdominal abscess or fistula.
  • Previous or current gastrointestinal dysplasia.
  • History of surgery for ulcerative colitis or major intestinal surgery requiring general anesthesia, or likely to require such surgery during the study.
  • Evidence of pathogenic intestinal infection, including Clostridium Difficile infection within 30 days before screening, or positive tests for intestinal pathogens at screening.
  • Chronic recurring or active viral infections making participation unsuitable.
  • Unable to take oral medications or with conditions affecting absorption, or receiving/planning total parenteral nutrition during the study.
  • Received treatments defined in the protocol that exclude enrollment.
  • History of recurrent or disseminated herpes zoster or cytomegalovirus infection.
  • Risks of tuberculosis as defined in the protocol.
  • Known allergy to investigational product or its components, or multiple drug/food allergies.
  • Unstable or uncontrolled significant allergic, hematological, endocrine/metabolic, coagulation, immunologic, pulmonary, cardiovascular, hepatic (except hepatic steatohepatitis), digestive (except ulcerative colitis), genitourinary, psychiatric, oncologic, neurological diseases or other medical disorders making participation unsafe.
  • Illness likely to require systemic glucocorticosteroids during the study.
  • Major organ surgery or significant trauma within 28 days before randomization or likely to require surgery during the study.
  • History of any malignancy within 5 years except successfully treated nonmelanoma skin cancer, basal cell carcinoma, or localized carcinoma in situ of the cervix.
  • Abnormal screening results as defined in the protocol.
  • Poorly controlled hypertension despite medication at screening.
  • Clinically significant abnormal ECG, including QTcF >450 msec for males and >470 msec for females.
  • Difficulty with venous blood collection, history of acupuncture syncope, or blood phobia.
  • Contraindications to colonoscopy.
  • History of alcohol or drug abuse within 3 months before screening.
  • Participation in other drug or device clinical trials within 30 days before screening or currently participating in another clinical trial.
  • Any condition deemed by the investigator to interfere with safety evaluation or study compliance.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 28 locations

1

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Actively Recruiting

2

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Actively Recruiting

3

Guangzhou First People's Hospital

Guangzhou, Guangdong, China

Actively Recruiting

4

The First Affiliated Hospital,Sun Yat-sen University

Guangzhou, Guangdong, China

Actively Recruiting

5

Huizhou First Hospital

Huizhou, Guangdong, China

Actively Recruiting

6

The People's Hospital of Guangxi Zhuang Autonomous Region

Nanning, Guangxi, China

Actively Recruiting

7

The Second Hospital of HeBei Medical University

Shijiazhuang, Hebei, China

Actively Recruiting

8

The First Affiliated Hospital of Henan University of Science & Technology

Luoyang, Henan, China

Actively Recruiting

9

The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China

Actively Recruiting

10

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Actively Recruiting

11

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

Not Yet Recruiting

12

The First Affiliated Hospital of University of South China

Hengyang, Hunan, China

Not Yet Recruiting

13

ZhongDa Hospital Southeast University

Nanjing, Jiangsu, China

Actively Recruiting

14

The First Affiliated Hospital of Gannan Medical University

Ganzhou, Jiangxi, China

Actively Recruiting

15

Meihekou Central Hospital

Tonghua, Jilin, China

Actively Recruiting

16

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Actively Recruiting

17

Binzhou Medical University Hospital

Binzhou, Shandong, China

Actively Recruiting

18

Tai 'an City Central Hospital

Taian, Shandong, China

Actively Recruiting

19

Longhua Hospital Shanghai University of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, China

Not Yet Recruiting

20

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Actively Recruiting

21

First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Actively Recruiting

22

Xi'an Central Hospital

Xian, Shanxi, China

Not Yet Recruiting

23

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

Actively Recruiting

24

West China School of Medicine and West China Hospital Sichuan University

Chengdu, Sichuan, China

Actively Recruiting

25

Tianjin People's Hospital

Tianjin, Tianjin Municipality, China

Actively Recruiting

26

The First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Actively Recruiting

27

Lishui Central Hospital

Lishui, Zhejiang, China

Not Yet Recruiting

28

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Actively Recruiting

Loading map...

Research Team

Y

Yang Deng

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) | DecenTrialz